UBS Global Enhanced Equity Income Fund C Inc
Category Global Equity Income
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price
32.59p
-0.18p (-0.55%)
Fund Code
UBGNI
BL0RSP8
GB00BL0RSP87
Prices updated as at 28 Mar 2025
Prices in GBX
Investment objective
The Fund aims to generate at least 110% of the income of the MSCI ACWI (GBP hedged) before the deduction of charges in any 12 month period through investment in the UBS (Lux) Equity SICAV – Global Income Sustainable (USD), a sub-fund of the UBS (Lux) Equity SICAV. The Fund invests at least 85% of its assets in the UBS (Lux) Equity SICAV – Global Income Sustainable (USD) (the "Master Fund"), a sub-fund of the UBS (Lux) Equity SICAV.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, SDR Consumer facing disclosure, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Growth
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk & rating
- Management
Annual performance (%)
Year | This fund | Global Equity Income |
---|---|---|
31 Dec 14 - 31 Dec 15 | 1.84 | 2.62 |
31 Dec 15 - 31 Dec 16 | 8.86 | 25.75 |
31 Dec 16 - 31 Dec 17 | 12.01 | 8.84 |
31 Dec 17 - 31 Dec 18 | -9.16 | -5.91 |
31 Dec 18 - 31 Dec 19 | 16.28 | 16.92 |
31 Dec 19 - 31 Dec 20 | -7.99 | 1.89 |
31 Dec 20 - 31 Dec 21 | 13.71 | 18.25 |
31 Dec 21 - 31 Dec 22 | -4.19 | -0.77 |
31 Dec 22 - 31 Dec 23 | 7.61 | 7.28 |
31 Dec 23 - 31 Dec 24 | 15.66 | 10.39 |
Trailing returns (%)
Year | This fund | Global Equity Income |
---|---|---|
1 Day | -0.55 | -0.14 |
1 Month | -1.00 | -2.38 |
3 Months | 3.35 | 1.53 |
6 Months | 2.84 | 3.13 |
1 Year | 11.93 | 6.40 |
3 Years annualised | 7.65 | 6.76 |
5 Years annualised | 10.63 | 12.30 |
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.